GH Secretagogues in Sports: The Athletic Appeal
GH Peptides and Performance
S2 classification on WADA's Prohibited List
Growth hormone secretagogues occupy category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) on the World Anti-Doping Agency's Prohibited List, banned at all times both in and out of competition.
WADA Prohibited List, 2025
WADA Prohibited List, 2025
View as imageGrowth hormone secretagogues (GHS) are among the most commonly encountered peptides in sports doping. These compounds stimulate the body's own production of growth hormone by activating the ghrelin receptor (GHSR-1a) or the growth hormone-releasing hormone (GHRH) receptor, raising GH and IGF-1 levels without directly injecting exogenous growth hormone. Athletes are drawn to the promise of enhanced recovery, increased lean mass, and reduced body fat. The reality documented in clinical trials is more complicated than the marketing.
Every GH secretagogue is prohibited under section S2 of the World Anti-Doping Agency's Prohibited List. This includes peptide secretagogues (GHRP-2, GHRP-6, ipamorelin, hexarelin), GHRH analogs (sermorelin, tesamorelin, CJC-1295), and the oral non-peptide ghrelin mimetic ibutamoren (MK-677). The ban applies at all times, in and out of competition, with no threshold concentration. Any detectable presence constitutes an anti-doping rule violation regardless of the amount found. For the broader context of how IGF-1 drives muscle growth signaling, see the pillar article on IGF-1 and muscle.
Key Takeaways
- MK-677 increased lean fat-free mass by 1.1 kg over 12 months in healthy elderly adults, but produced no improvement in strength or physical function (Nass et al., Annals of Internal Medicine, 2008)
- A case report of combined LGD-4033 and MK-677 use showed altered body composition biomarkers and increased androgenic hormone receptor content in skeletal muscle (Cardaci et al., Experimental Physiology, 2022)
- Anti-doping laboratories can detect MK-677 in equine hair samples following oral administration, extending detection windows beyond blood and urine (Viljanto et al., Drug Testing and Analysis, 2023)
- Seized doping materials contained glycine-modified growth hormone secretagogues not found in pharmaceutical databases, indicating black-market chemical innovation (Gajda et al., Drug Testing and Analysis, 2019)
- A decade review of doping control analysis identified small peptide detection (2-10 kDa) as one of the most technically challenging areas in anti-doping science (Judak et al., Analytical and Bioanalytical Chemistry, 2021)
- Novel capromorelin derivatives demonstrated oral GH secretagogue receptor agonist activity, representing a new generation of GHS compounds under pharmaceutical development (Xu et al., 2025)
What GH Secretagogues Actually Do
GH secretagogues fall into two mechanistic classes. GHRH analogs (sermorelin, tesamorelin, CJC-1295) bind the GHRH receptor on pituitary somatotrophs and directly stimulate growth hormone release. Ghrelin receptor agonists (GHRP-2, GHRP-6, ipamorelin, hexarelin, MK-677) bind the growth hormone secretagogue receptor 1a (GHSR-1a) and amplify the pulsatile pattern of GH secretion. When both receptor types are activated simultaneously, the GH response is synergistic: larger than the sum of either stimulus alone.
The downstream effects cascade through the GH/IGF-1 axis. Elevated GH stimulates hepatic IGF-1 production, which drives protein synthesis in skeletal muscle, enhances lipolysis in adipose tissue, and promotes collagen synthesis in tendons and ligaments. GH also promotes nitrogen retention, increases amino acid transport into cells, and stimulates chondrocyte proliferation in cartilage. This biological logic is why athletes pursue GH secretagogues: the promise of faster recovery, leaner body composition, enhanced tissue repair, and potentially stronger connective tissue.
The appeal is amplified by the perception that secretagogues are "safer" than injecting recombinant growth hormone directly. By stimulating the body's own GH production, secretagogues maintain the natural pulsatile pattern of hormone release rather than creating the continuous supraphysiological levels associated with exogenous GH injection. The body's feedback mechanisms remain intact, which theoretically limits the risk of GH excess. Whether this theoretical safety advantage translates to meaningful clinical differences in side effects is unknown, as no head-to-head comparisons exist between long-term secretagogue use and long-term exogenous GH use in athletic populations.
Tyler et al. (2026) characterized the pharmacokinetic and pharmacodynamic profile of a novel growth hormone secretagogue receptor agonist in a randomized controlled study, confirming dose-dependent elevation of GH and IGF-1 with oral administration. The study demonstrated that newer GHS compounds can achieve reliable GH elevation through oral dosing, reducing the injection requirement that characterized earlier peptide secretagogues.[1]
Xu et al. (2025) developed capromorelin derivatives as oral GH secretagogue receptor agonists, expanding the chemical space of ghrelin receptor pharmacology. These compounds demonstrated potent receptor activation and favorable oral bioavailability, representing a new generation of GHS beyond the classic peptide secretagogues.[2]
The Clinical Evidence Gap
The central question for athletes is whether GH secretagogues improve performance. The answer from controlled clinical trials is disappointing relative to expectations.
Nass et al. (2008) conducted the definitive randomized, double-blind, placebo-controlled trial of MK-677 in 65 healthy older adults over 12 months. The results: daily MK-677 increased lean fat-free mass by 1.1 kg compared to a 0.5 kg loss with placebo, and elevated GH and IGF-1 to levels typical of healthy young adults. But MK-677 produced no improvement in strength, physical function, or endurance. Body weight increased 2.7 kg in the MK-677 group (vs. 0.8 kg with placebo), and insulin sensitivity declined with a 0.28 mmol/L increase in fasting glucose. Some of the measured "lean mass" gain may reflect increased intracellular water retention rather than new contractile muscle tissue, a known confound in GH-related body composition measurements.[3]
This pattern repeats across the GH secretagogue literature: elevated GH/IGF-1 levels, modest lean mass changes that may partly reflect water retention, no measurable functional improvement, and metabolic side effects including insulin resistance. The disconnect between hormone levels and performance outcomes is the central finding that athletes and coaches often ignore or rationalize away.
The pattern parallels the broader evidence on exogenous growth hormone and athletic performance, which consistently shows that supraphysiological GH levels do not translate to proportional strength or speed gains in healthy individuals. The expectation that more growth hormone equals more muscle and better performance is biochemically intuitive but empirically unsupported in controlled clinical settings with healthy subjects. For the detailed evidence review on this disconnect, see the sibling article on do GH peptides actually improve strength and power.
Cardaci et al. (2022) published a detailed case report of an individual using both LGD-4033 (a selective androgen receptor modulator) and MK-677 simultaneously over a multi-week cycle, documenting changes in body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content through serial biopsies and blood work. The report illustrated the polypharmacy approach common in sports doping, where GH secretagogues are combined with anabolic agents rather than used in isolation. Separating the effects of each compound becomes impossible when they are stacked, which is precisely how most athletes use them.[4]
The Recovery Argument
Where the performance evidence is weak, the recovery argument is more plausible. GH and IGF-1 play documented roles in tissue repair: collagen synthesis in tendons and ligaments, satellite cell activation in damaged muscle fibers, and bone mineral density maintenance. Athletes in collision sports, combat sports, and endurance disciplines face chronic tissue damage that limits training volume and career longevity.
The theory is that GH secretagogues accelerate repair between training sessions, allowing higher training loads rather than directly improving acute performance. This hypothesis has biological support but limited clinical validation in healthy athletic populations. Most GH/IGF-1 recovery studies used exogenous recombinant growth hormone injection rather than secretagogues, and even those results are mixed.
Mantuano et al. (2025) provided indirect support from a preclinical model, showing that JMV2894 (a growth hormone secretagogue) had therapeutic effects in a Duchenne muscular dystrophy mouse model. The GHS improved muscle pathology markers, suggesting that ghrelin receptor activation can influence muscle repair processes beyond simple GH elevation.[5]
Lu et al. (2024) demonstrated that anamorelin and ipamorelin (two GH secretagogue receptor agonists) inhibited cisplatin-induced weight loss and muscle wasting in animal models, providing evidence that ghrelin receptor activation has anti-catabolic effects independent of its GH-releasing properties.[6]
These findings support the biological plausibility of recovery benefits but do not demonstrate performance enhancement in healthy athletes. The gap between preventing muscle wasting in disease models and enhancing recovery in already-healthy, well-nourished athletes is substantial. Disease models involve catabolic states where the body's repair mechanisms are overwhelmed; the intervention prevents pathological loss. Athletic recovery involves optimizing already-functional repair mechanisms; the marginal gain, if any, is much smaller and harder to measure.
Berlanga-Acosta et al. (2024) demonstrated another protective application, showing that GHRP-6 prevented doxorubicin-induced myocardial and extra-myocardial damage through activating anti-inflammatory and anti-apoptotic signaling cascades. While this confirms that ghrelin receptor activation has tissue-protective effects, the clinical context (chemotherapy cardioprotection) is far removed from athletic recovery.[13]
For how natural exercise-induced GH release compares to exogenous peptide stimulation, see the sibling article on natural GH release from exercise vs exogenous peptides. For how growth hormone relates to athletic performance more broadly, see that sibling article.
Detection and the Anti-Doping Challenge
Detecting GH secretagogue use presents unique analytical challenges that distinguish peptide doping from classical anabolic steroid doping. Steroids and their metabolites persist in urine for days to weeks and are detectable through well-established gas chromatography-mass spectrometry methods. GH secretagogue peptides are small (typically 2-10 kDa), rapidly metabolized, and present in blood and urine at sub-nanogram concentrations with detection windows measured in hours rather than days.
The indirect nature of the doping mechanism adds another layer of difficulty. Unlike exogenous growth hormone, which can be distinguished from endogenous GH through isoform ratios (the GH isoform test detects the altered ratio caused by injecting a single recombinant GH isoform), GH secretagogues stimulate the body's own pituitary to produce growth hormone through normal physiological pathways. The resulting GH is identical to naturally produced hormone in all respects. Only the secretagogue molecule itself, or its metabolites, can be directly detected.
Judak et al. (2021) reviewed a decade of progress in small peptide doping control analysis, noting that while detection sensitivity has improved through liquid chromatography-mass spectrometry advances, detection windows remain narrow (typically hours to days) and many peptide doping agents can only be found through targeted analysis rather than routine screening.[7]
Gomez-Guerrero et al. (2022) described synthetic peptides as "a powerful tool for an analytical challenge" in doping control, developing reference standards and metabolite profiles for emerging GH secretagogues that had not previously been characterized by anti-doping laboratories.[8]
Viljanto et al. (2023) extended the detection window by demonstrating that MK-677 could be identified in equine hair samples following oral administration. Hair analysis provides a retrospective detection window of weeks to months, compared to hours for blood and urine. If validated for human samples, hair analysis could transform retrospective doping detection for oral GH secretagogues.[9]
Philip et al. (2022) characterized the metabolic profile of ibutamoren (MK-0677) in thoroughbred horse samples, identifying specific metabolites that serve as longer-lasting biomarkers of use. These metabolite profiles are being adapted for human anti-doping applications.[10]
The Black Market Problem
Athletes who use GH secretagogues typically obtain them from unregulated online sources. This creates a secondary health risk beyond the regulatory consequences of a positive test.
Gajda et al. (2019) analyzed seized doping materials and found glycine-modified growth hormone secretagogues not cataloged in any pharmaceutical database. These novel compounds represent deliberate chemical modifications designed to evade anti-doping detection while preserving biological activity. The modifications may also alter the safety profile of the parent compound in unpredictable ways, as no toxicology data exists for these designer peptides.[11]
Thevis et al. (2014) documented the accelerating pace of novel peptide doping agents, noting that anti-doping laboratories consistently encounter compounds that have never been through any safety evaluation, let alone clinical trials. The gap between black-market chemical innovation and anti-doping analytical capability continues to widen. By the time a laboratory develops a validated test for one novel secretagogue, chemists have already synthesized several more. This arms race has no obvious resolution: the structural diversity of possible ghrelin receptor agonists is enormous, and each new compound requires its own reference standard and metabolite characterization before it can be reliably detected.[12]
The quality of black-market GH secretagogues is another concern. Independent analyses of products sold online as "research chemicals" or "peptides for research use only" have found contamination with other active substances, incorrect dosing, degraded product, and in some cases, entirely different compounds than what was listed on the label. Athletes who use these products have no way to verify what they are actually taking, the dose they are receiving, or the purity of the material. This contrasts with pharmaceutical-grade GH secretagogues (tesamorelin for HIV lipodystrophy, macimorelin for adult GH deficiency diagnosis) that undergo rigorous manufacturing and quality control.
For detailed profiles of individual GH secretagogues used by athletes, see MK-677 (ibutamoren), hexarelin, and can growth hormone peptides build muscle.
The Bottom Line
Growth hormone secretagogues remain among the most popular peptides in sports despite being banned by WADA and lacking convincing evidence for performance enhancement. The best controlled trial (MK-677 for 12 months) showed a 1.1 kg lean mass increase but no strength or functional improvement. The recovery hypothesis has biological plausibility but minimal clinical validation in athletic populations. Anti-doping detection faces narrow windows and rapid evolution of designer compounds. The disconnect between athletic demand and scientific evidence for these peptides is substantial: GH secretagogues reliably elevate GH and IGF-1, but elevated hormones do not reliably translate to enhanced performance.